Evidence map›Paper›PMID 36678916›Full record

ArticlePharmaceutics2023

Enhancing Intradermal Delivery of Lidocaine by Dissolving Microneedles: Comparison between Hyaluronic Acid and Poly(Vinyl Pyrrolidone) Backbone Polymers.

Delly Ramadon, Lissa Florencia Putri Sutrisna, Yahdiana Harahap, Kurnia Sari Setio Putri, Fathin Ulayya, Pietradewi Hartrianti, Qonita Kurnia Anjani, Ryan F Donnelly

Open access · goldAbstract read
In one paragraph

Article in Pharmaceutics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
4.6field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 41 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Delly RamadonFaculty of Pharmacy, Universitas Indonesia, Depok 16424, Indonesia.ORCID 0000-0002-2847-9610
Lissa Florencia Putri SutrisnaFaculty of Pharmacy, Universitas Indonesia, Depok 16424, Indonesia.
Yahdiana HarahapFaculty of Pharmacy, Universitas Indonesia, Depok 16424, Indonesia.
Kurnia Sari Setio PutriFaculty of Pharmacy, Universitas Indonesia, Depok 16424, Indonesia.
Fathin UlayyaFaculty of Pharmacy, Universitas Indonesia, Depok 16424, Indonesia.
Pietradewi HartriantiSchool of Life Sciences, Indonesia International Institute for Life Sciences, Jakarta 13210, Indonesia.ORCID 0000-0002-5315-6741
Qonita Kurnia AnjaniMedical Biology Centre, School of Pharmacy, Queen's University Belfast, 97 Lisburn Road, Belfast BT9 7BL, UK.ORCID 0000-0002-4809-550X
Ryan F DonnellyMedical Biology Centre, School of Pharmacy, Queen's University Belfast, 97 Lisburn Road, Belfast BT9 7BL, UK.ORCID 0000-0002-0766-4147
University of Indonesia · IDQueen's University Belfast · GBIndonesia International Institute for Life Sciences · ID

Funding

University of Indonesia NKB-546/UN2.RST/HKP.05.00/2022
6 · The paper itself

Abstract

Lidocaine hydrochloride (LiH), an amide-type local anesthetic agent, is commonly used in dermatological procedures. LiH is categorized as a BCS (biopharmaceutics classification system) class III group, which has high solubility and poor permeability. It should be noted that, in this context, LiH is intended as a local anesthetic, so the level of LiH in systemic circulation should be minimized to avoid toxicity and unwanted side effects such as hypotension and bradycardia. This study aimed to formulate and evaluate LiH-loaded dissolving microneedles (DMNs) with different polymer bases. Moreover, an in vitro permeation study using Franz diffusion cells and in vivo study were also performed. LiH-loaded DMNs were prepared using polymer groups of poly(vinyl pyrrolidone) (PVP-K30) and hyaluronic acid (HA). DMNs were created using the micro-molding method with centrifugation. The formulations selected based on the evaluation were F3 (HA 10%) and F5 (PVP-K30 25%). Based on the in vitro permeation study, the amount of drug permeated and deposited in the skin at F3 (HA 10%) was 247.1 ± 41.85 and 98.35 ± 12.86 μg, respectively. On the other hand, the amount of drug permeated and deposited in the skin at F5 (PVP-K30 25%) was 277.7 ± 55.88 and 59.46 ± 9.25 μg, respectively. Our in vivo drug-permeation study showed that only one rat from the PVP-K30 polymer group-with a concentration of 150.32 ng/mL-was detected on rat plasma. Therefore, LiH can be formulated into a DMN and can be deposited in the skin with a safe concentration of the drug permeating into systemic circulation.

Indexed as

dissolving microneedleshyaluronic acidhydrosolubleintradermal drug deliverylidocainelocal anesthesiaPVP

Identifiers

PMID36678916
PMCPMC9864429
OpenAlexW4316464216

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.